Loading…
Lobbying Spend
—
Filings
14
Firms Hired
1
Active Period
2007–2010
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1548
America's Affordable Health Choices Act of 2009
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: HR 3200
America's Affordable Health Choices Act of 2009
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: HR 3200
Preserving Equitable Access to Community-based Home Health (PEACH) Act of 2009
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: HR 3495
Preserving Equitable Access to Community-based Home Health (PEACH) Act of 2009
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: HR 3495
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2010 · first_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548, HR 3200, HR 3495.
Client expense: — · Firm income: $10,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · fourth_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Pathway for Biosimilars Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · third_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: S. 726
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Promoting Innovation and Access to Life-Saving Medicine Act
2009 · second_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1427
Pathway for Biosimilars Act
2009 · second_quarter · Firm: JENNINGS POLICY STRATEGIES
Advocate for the creation of a regulatory pathway for generic biologic medications and policies that promotes innovation and competition and ensures affordability in the pharmaceutical marketplace, including but not limited to H.R. 1427, S. 726 and H.R. 1548).
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1548
Source: Senate LDA